trial

A Study of Olanzapine in Patients With Schizophrenia

NCTId NCT00970281
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 91 (actual)
Sponsored by Eli Lilly and Company
Primary completion 2011-04
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
91 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2009-09
Primary completion
2011-04
Eligibility
ALL · 20 Years · 64 Years

Interventions & indications

Drugs
Olanzapine

Sponsors

Eli Lilly and CompanyLead Sponsor

Investigators

1
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)Study Director

Sites

11 total
Aichi, JapanGunma, JapanHokkaido, JapanKanagawa, JapanKumamoto, JapanNara, JapanOkinawa, JapanOsaka, JapanSaitama, JapanTokyo, JapanYamaguchi, Japan

Linked catalysts

1
A Study of Olanzapine in Patients With Schizophrenia — primary completion2011-04

Facts & assertions

4 sourced
Enrollment
91
Phase
PHASE3
Primary Completion Date
2011-04
Status
COMPLETED
relationships
The graph out of here
drug
Olanzapine
drug
lead_sponsor
Eli Lilly and Company
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)
person